Journal: bioRxiv
Article Title: The combination of BCL-xL PROTAC and mTOR inhibitor sensitizes pancreatic ductal adenocarcinoma to KRAS G12D inhibitor treatment by enhancing apoptosis induction
doi: 10.64898/2026.01.05.697773
Figure Lengend Snippet: Immunoblot analyses of phosphorylated- and total- ERK, AKT and S6, BIM extra-long isoform (BIM EL ) and NOXA in AsPC1 (a), HPAC (b), SW1990 (c), and PANC1 cells (d) after they were treated with indicated concentrations of MRTX1133 for 24 h. The β-tubulin was used as an equal loading control. e-h. Densitometric analysis of BIM EL and NOXA immunoblots in AsPC1 (e), HPAC (f), SW1990 (g), and PANC1 cells (h). Immunoblots detect three isoforms of BIM i.e., short isoform (BIM S ), long isoform (BIM L ) and extra-long isoform (BIM EL ). Among them, BIM EL is the major isoform and is shown here. i-l. mRNA expression levels of BIM-coding gene BCL2L11 in AsPC1 (i), HPAC (j), SW1990 (k), and PANC1 cells (l) after 24 h treatment with MRTX1133. m-p . mRNA expression levels of NOXA-coding gene PMAIP1 in AsPC1 (m), HPAC (n), SW1990 (o), and PANC1 cells (p) after 24 h treatment with MRTX1133. Data in i-p are presented as mean ± SD (n= 3 biological replicates). ** p <0.01, *** p <0.001, **** p <0.0001, ns p >0.05 i.e., not significant compared to untreated (control) cells as determined by one-way ANOVA and Dunnett’s multiple comparisons test. Since ERK1 and ERK2 have very close molecular weights (∼44 and ∼42 kDa), the two bands appeared as a single merged band in panels a-d (and subsequent figures) due to limited resolution in gradient gels that we have used.
Article Snippet: The mRNA expressions were quantified using pre-designed Taqman probes of BCL2L11 (Assay #Hs00708019_s1) and PMAIP1 (Assay # Hs00560402_m1) from Thermo Fisher.
Techniques: Western Blot, Control, Expressing